Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
Naci H, de Lissovoy G, Hollenbeak C, Custer B, Hofmann A, McClellan W, Gitlin M. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. J Med Econ. 2012; 15(2):293-304.